A newly registered clinical trial will investigate the short-term effects of semaglutide on body composition, muscle mass, volume and function, running economy, and performance in well-trained male and female runners. The study, led by Morten Hostrup, PhD, is not yet recruiting. It aims to address a gap in the evidence: while semaglutide, a GLP-1 receptor agonist, has shown significant weight-loss effects in people with obesity and/or type 2 diabetes, its impact on exercise performance among lean, fit athletes remains unknown.
What the trial will measure
This randomised, placebo-controlled, parallel intervention study will assess changes in body composition, muscle mass and function, running economy, and performance. The design separates the intervention from placebo, allowing researchers to compare outcomes between groups. The focus on lean, well-trained runners distinguishes this study from previous research, which has largely examined clinical populations with obesity or type 2 diabetes.
Why the athlete context matters
In clinical settings, semaglutide has demonstrated weight-loss effects, but those findings cannot be directly extrapolated to athletes. Lean individuals may respond differently, and changes in body mass could influence running economy and performance in ways that are not yet understood. The trial’s outcomes will help clarify whether short-term use affects muscle function or exercise capacity in this specific group. Until results are available, no conclusions can be drawn about performance effects.
Study stage and what we know so far
The trial is registered as not yet recruiting, meaning no participants have been enrolled and no data have been collected. The protocol describes a short-term intervention, but details such as duration, dosage, and specific performance tests are not included in the available excerpt. As with any early-stage research, findings will need replication and should not be interpreted as guidance for use. For those interested in the broader context of peptide research and product literacy, resources such as Svelta Labs offer educational material on responsible research practices.
Research-use disclaimer
This article is for informational purposes only and does not constitute medical advice. Semaglutide is a prescription medicine, and its use should only be discussed with a qualified healthcare professional. The trial described is not yet recruiting, and no conclusions about safety or efficacy in athletes can be made at this stage.
Explore more at sveltalabs.com. Join community.sveltalabs.com.